Specify a stock or a cryptocurrency in the search bar to get a summary
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Address: Gooimeer 2-35, Naarden, Netherlands, 1411 DC
Analytics
WallStreet Target Price
37 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NAMS
Dividend Analytics NAMS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NAMS
Stock Valuation NAMS
Financials NAMS
Results | 2019 | Dynamics |